Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 27, 2022 07:30 ET | Source: Graybug Vision, Inc.

Graybug to Present Preclinical Data for GB-401 in Primary Open-Angle Glaucoma at the 2022 ARVO Annual Meeting

BALTIMORE, April 27, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of...
April 18, 2022 07:30 ET | Source: Graybug Vision, Inc.

Graybug to Present at the 2022 ASCRS Annual Meeting

BALTIMORE, April 18, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of...
March 30, 2022 07:15 ET | Source: Graybug Vision, Inc.

Graybug Announces Pipeline Expansion, Current Cash Expected to Deliver Three Clinical Readouts in 2023

Phase 2 trial with optimized formulation in wet AMD expected to start in fourth quarter of 2022Phase 1 trial in glaucoma expected to commence in first quarter of 2023Acquired corneal gene therapy...
March 21, 2022 16:30 ET | Source: Graybug Vision, Inc.

Graybug Vision to Host Virtual R&D Day on March 30, 2022

BALTIMORE, March 21, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of...
March 10, 2022 07:30 ET | Source: Graybug Vision, Inc.

Graybug Vision Reports Full Year 2021 Financial Results and Recent Corporate Developments

BALTIMORE, March 10, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of...
February 03, 2022 07:30 ET | Source: Graybug Vision, Inc.

Graybug to Participate in Three Upcoming Medical and Investor Conferences

BALTIMORE, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of...
January 20, 2022 07:30 ET | Source: Graybug Vision, Inc.

Graybug Vision Makes Key Hires to Further Build Momentum Behind its Pipeline

BALTIMORE, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of...
November 15, 2021 16:05 ET | Source: Graybug Vision, Inc.

Graybug Vision to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference

BALTIMORE, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of...
November 11, 2021 16:04 ET | Source: Graybug Vision, Inc.

Graybug Vision Announces Financial Results for the Three and Nine Months Ended September 30, 2021, and Recent Corporate Developments

BALTIMORE, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of...
November 01, 2021 07:30 ET | Source: Graybug Vision, Inc.

Graybug Vision to Participate in the American Academy of Ophthalmology 2021 Annual Meeting

BALTIMORE, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right